very interesting new idea brought to my attention by RHPS today.

http://www.phosphagenics.com/ is the company website and

www.cohenresearch.com has an interesting report on them

with new phosphorylation techniques (inserting a phosphate group into the chemical structure to make it much more readily absorbed into the body), they aim to deliver more effectively previously hard to transmit drugs to the body - Vitamin E (already successfully launched in US), morphine (much smaller amounts needed, so fewer side effects), and others

talks with FDA started on basis of an enhanced delivery rather than enhanced drug action - much simpler process

recently gained Aus government grant of Aus$1.7 to fund Phase I and Pre-Phase II human trials of transdermal morphine delivery

a Material Evaluation Agreement signed with major US pharma to apply PSG's technology to its patented systems

forward PE of 0.54 (yes I did get the decimal point in the right place!)

shares up from about 7p to 12p over last 3 months

listed on Ausraillian Stock Market and London AIM

must be interesting to watch at least. DYOR then do it again to make sure I'm not dreaming.

check it out and ket me know what you think

cheers
SD

Anyone know anyting about ALZA? Which country is it based in? Waht's its track-record with what other related products?

Sorry, no time to DMOR today!

sd

sd
just did a quick google search, loads of info. As you i do not have the time at the moment, be back later.

Taken from another BB.

an update by CS as well........

Phosphagenics Development agreement with Alza Corporation

Phosphagenics has entered into a development agreement with Alza Corporation, a leading drug delivery company and a subsidiary of Johnson & Johnson. Under the terms of the agreement Alza will test a range of its drugs with TPM-01, Phosphagenics transdermal drug delivery platform.

Analysis
This is a very important deal for Phosphagenics, as it provides validation for its transdermal platform technology, TPM-01. As part of the development agreement Alza will fully fund testing of TPM-01 with a broad range of drugs. Any positive outcomes of the tests should lead to a full clinical development programme. We believe that this should trigger milestone payments and a future royalty stream for Phosphagenics.

Action

Phosphagenics has already demonstrated that it can deliver a broad range of drugs and chemicals across animal skin, including insulin, parathyroid hormone, fentanyl, estrodiol and testosterone. The company has also successfully delivered Morphine transdermally using TPM-01; therefore we are confident that the technology will be used successfully with some of the drugs that Alza will test. We expect that there will be further newsflow from this collaboration in 2006.

This relationship with Alza is very valuable for Phosphagenics. The company is yet to license a partner for its lead product TPM-01/Morphine and we believe that Alza could be a potential partner.

The upside therefore possible from the transdermal work currently being undertaken is significant. We eagerly await the results of Phase II data on the morphine formulation. More importantly the work relating to cholesterol lowering and the inhibition of plaque formation in arteries offers significant upside. The shares are clearly undervalued. Our price target in valuation terms remains 170 million

sd
as requested, owned by Johnson & Johnson

ALZA Corporation is the leading provider of drug delivery solutions with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies. ALZA partners with pharmaceutical and biotechnology companies to develop and manufacture pharmaceutical products that enhance healthcare for millions of patients worldwide.

Founded in 1968 by Dr. Alejandro Zaffaroni, ALZA has over 35 years of experience in scientific innovation. ALZA technology has been incorporated in 30 commercialized products marketed in more than 80 countries. More than 3,000 US and foreign patents are active or pending.



A Problem-Solving Approach
ALZA provides value to our partners in all phases of product development, from initial concept, through manufacturing and commercialization. Many of our collaborations begin in the early phases of product development, using our pharmacologic discovery process to identify optimal delivery profiles. This process pushes the boundaries of drug delivery, and yields highly attractive options for partner companies to commercialize novel therapies.



A Center for Scientific Excellence
Our expertise spans the physical sciences, biology, engineering, clinical research and pharmacology. As a Johnson & Johnson company, ALZA extends a global reach and is dedicated to developing unmatched scientific solutions to some of the world's most critical healthcare needs.



Inventing the Future
As new compounds emerge from biotechnology and genetic research, ALZA technologies continue to evolve, providing unique delivery platforms that extend the potential of important new therapies. Year after year, we deliver results that benefit healthcare and expand market opportunities for our pharmaceutical partners

forest
Interesting - thanks
sd

sd
Something in today's Daily Mail on psg, i have not read it.

Phosphagenics Limited
14 November 2005


14 November 2005


Phosphagenics Limited


Placement of Shares


Biotechnology company Phosphagenics Limited ('Phosphagenics') (ASX Code: POH;
AIM Code: PSG) advises that it is to raise A$11.25 million (Stg.4.68 million)
via a placement of approximately 46.875 million fully paid ordinary shares to
leading overseas and domestic institutions, and other sophisticated investors,
at 24 cents (10 pence) per share. The capital raising will provide funding for
Phosphagenics' core R&D program and general expenses.


It is expected that trading in the new shares on the Australian Stock Exchange
and the London Stock Exchange's Alternative Investment Market will commence on
or around 17 November 2005.


Mr Harry Rosen, President & Executive Director said that the company was very
pleased with the response from investors. 'Support from international investors
was particularly pleasing and we believe it reflects their confidence in our
ability to meet our milestone targets and deliver on our strategic plan,' he
said.


The placement in Australia was arranged by BBY Limited, Lead Manager to the
transaction, and in the UK by London-based Collins Stewart Limited.


Mr Rosen said: 'The funds raised will be used to further develop our portfolio
of pharmaceutical and nutraceutical drugs including Phosphagenics'
globally-competitive, transdermal technology which is uniquely safe and
effective and has the potential to be applied to an extraordinarily broad range
of drugs.'


About Phosphagenics Limited


Phosphagenics Limited is a pharmaceutical and nutraceutical company with a
diversified portfolio of technologies encompassing drug delivery, drug
enhancement, and active ingredients for dietary supplements, functional foods
and personal care products.


Phosphagenics is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG).


For further information, please contact Mr Harry Rosen, Phosphagenics Limited on
+61 3 9605 5900

.

Something cooking here, 130,000 buy yesterday, 50k today, yet no price movement.
keep an eye or two on these, imho.

Phosphagenics Limited
18 January 2006


Phosphagenics Limited


18 January 2006


Trial Results


Phosphagenics announces successful results from a Phase Ib clinical trial of its
transdermal morphine gel

Melbourne, VIC, Australia, 18 January 2006, Phosphagenics Limited ('
Phosphagenics'), the Australian Stock Exchange (ASX:POH) and AIM (AIM:PSG)
listed pharmaceutical and nutraceutical company, today announces successful
completion of the Phase Ib clinical trial of its transdermal morphine gel,
TPM-01/Morphine. The study demonstrated that therapeutic levels of morphine in
plasma were achieved using Phosphagenics' transdermal delivery technology.
Phosphagenics now plans to seek approval for a Phase IIa study to assess the
efficacy of TPM-01/Morphine for relief of post-operative pain, which is expected
to commence in early 2006.

The Phase Ib study, conducted over a week at the Royal Adelaide Hospital, South
Australia was an 18-patient, single dose, open label, randomised study that
examined the pharmacokinetics of Phosphagenics' transdermally delivered morphine
gel. In the study, the morphine gel, administered via a single application to
the upper arm, achieved therapeutic blood morphine levels within 2 hours and
these were maintained for over 48 hours with full clearance occurring by 72
hours. These results mirrored those achieved in a Phase Ia study on TPM-01/M,
conducted to establish the tolerability and safety of the product. The TPM-01/
Morphine research is 50% funded by an R&D START grant of $1.7 million from the
Australian Government through AusIndustry.

TPM-01/Morphine was developed using the company's proprietary transdermal
penetration enhancer technology, TPM-01. TPM-01/Morphine is a non-invasive,
patient-friendly gel that delivers morphine through the skin into the
bloodstream. While oral administration of morphine produces dose spiking and
side effects including constipation, nausea, and drowsiness, Phosphagenics
believes that topical administration may eliminate many of these side effects
and offer the opportunity for sustained delivery of morphine for chronic pain
sufferers. The current longest acting morphine products provide therapeutic
blood levels for up to 24 hours, compared to over 48 achieved with TPM-01/
Morphine.

There is currently no commercially available transdermal morphine product. The
only transdermal opioid pain killer on the market is the drug fentanyl, with
sales in excess of US$ 2bn a year. Phosphagenics has recently shown that its
transdermal technology is also applicable to fentanyl, and its success in
improving the delivery of fentanyl across the skin offers opportunities for the
Company to offer fentanyl and morphine to prospective commercial partners as
part of a portfolio of transdermal pain products.

Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics,
said: 'Phosphagenics is very pleased that this Phase Ib study has successfully
confirmed the previous study which demonstrated the ability of TMP-01/Morphine
formulations to deliver therapeutic levels of morphine across the skin barrier.
The company will use the data from this and previous studies to progress the
product to the next stage of clinical development in this area of unmet medical
need'.


About Phosphagenics' TPM-01 transdermal carrier technology

TPM-01 utilises existing natural transport mechanisms to carry drugs across the
skin without disrupting the surface of the skin. In contrast, competing
technologies rely either on passive diffusion across skin membranes, and improve
drug penetration with solvents, enhancers or lasers that modify the properties
of the outermost layers of the skin, or on the use of electrical or thermal
technologies to 'push' drugs through the skin.

TPM-01 has anti-inflammatory and anti-erythema properties which minimise skin
irritation, can provide sustained transdermal delivery of drugs and can deliver
both small (e.g. morphine) and large (e.g. insulin) molecules through the skin.


About Phosphagenics Limited

Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for dietary supplements, functional foods and personal care
products. It is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). Further information regarding Phosphagenics can be
found at
www.phosphagenics.com

This company is massive in the range of what its patented technology can be applied to. It will take time to get approval worldwide, but I beleive it will happen. Good response to today's announcement (started yesterday actually - obviously information can be transdermally transmitted too - lol!). No analysis available or even really doable, but certainly a multi-bagger over 2-5 years potential.

sd

This bit is best, just hope everything goes well. Held these for ages.

There is currently no commercially available transdermal morphine product. The
only transdermal opioid pain killer on the market is the drug fentanyl, with
sales in excess of US$ 2bn a year. Phosphagenics has recently shown that its
transdermal technology is also applicable to fentanyl, and its success in
improving the delivery of fentanyl across the skin offers opportunities for the
Company to offer fentanyl and morphine to prospective commercial partners as
part of a portfolio of transdermal pain products.

Just wait till their vitamin E in soluble form gets approval to attack (sic) the heart market - bigger than morphine and bigger even than insulin market - 3 immense areas of growth aprt from the nutriceuticals opportunities. remember Astra Zedneca, Welcome, etc, etc I can still remember when they were this size - just.

sd

hi stockdog, followed you over here a few weeks ago and now thinking strongly towards getting in...though the years chart doesn't look to encouraging

GN

Glob Nom, the chart stinks, I know. But at this stage of a company in a very thin market for the shares, the chart is probably not so relevant.

Having studied chemistry at university, I have an affinity with the basic process they are doing here - phophorylation. It's "making a better light bulb" whose applications are literally endless. Just take soluble Vitamin E for cardiovascular and transdermal delivery of post-operative morphine and diabetic insulin, not to mention the more fashionable nutraceuticals. These two or three products are selling in to multi-billion dollar markets with no visible competition to the improvement they will offer once fully tested and approved. Approval for a new method of delivery is much less difficult than approval for a new drug per se.

So far they have proved themselves at each stage of technological development and regulatory approval, but I am sure we may still be some years away from break out. However, I have no problem imagining that this share could be 1.15 in 5 years time. The down side seems to have been mostly shaken out since I bought in at about 13.70 over the first 6 months of last year, barring any specific bad news, like failure to gain approval at any future stage. Although I'm down 23%, it's kind of irrellevant compared to the upside that will eventually out when the market is prepared to look at these seriously.

I'm a little light in my poprtfolio weighting on this one and it's one of my targets to top up as soon as any profit trimming (or stop lossing!) on other stocks frees up some more cash.

You (I) could have got in at 10.50p at the start of the year, as oppopsed to 12.50p offer now. But it will make no real difference to the proposition and the chances are equally likely we'll never see 10.50p again anyway.

So take a dabble, or paddle, or whatever it is you do to get your toes wet. This will give you an interest to get to learn all about this share and keep you awake for the time to put in serious money when it starts to make its first major move upwards.

WDIK, DYOR

sd

cheers SD, I think I've got my shoes and socks off but the water looks a little chilly......a little encouragement (or a push) and my toes will get dipped then I may well go for a swim.

GN

I'll hold the towel for you, but you've gotta make the ultimate decision. Good luck.

sd

Annual accounts published yesterday - the most boring uninformative stuff I've read in years, although full marks for thorough transparency. Unfortunately it tells you mor about Oz accounting standards than it does about the company. One small fact I gleaned is that Nutraceuticals division fulfilled last year's AGMS's prediction of breaking even in 2005 with a small profit of about Aus$111,000 - although who knows how the allocate central costs quite.

Frustrated by no proper Chairman or CEO's report on the activities of the company in the accounts I looked on their website and found 3 very nice reports from the AGM last May - see links below:-

http://www.phosphagenics.com/main/investors_presentations.htm

and a brokers update from Nov 2005 which makes good reading, valuing the SP at Aus$0.71 or about 28p compared to today's 10p:-

http://www.phosphagenics.com/main/Analyst_Coverage.htm

This is very much on my list to buy more whilst still at this price, when I can bear to free up some cash from my other holdings. Let's hope this year's AGM has as much to say about the company's activities and achievements as last years.

sd

I saw by chance the following report of a deal with Nestle Nutrition which may account for today's meteoric 0.25p rise. Why doesn't MaM pick this up in their RNS reports? Anyway, even though the SP has turned into a snail, one day all this positive progress will bear fruit IMHO.

sd

28 April 2006
PHOSPHAGENICS & NESTLNUTRITION SIGN AGREEMENT FOR DEVELOPMENT OF PHOSPHA E
FOR FOODS AND BEVERAGES
Melbourne, Australia and Vevey, Switzerland, 28 April 2006 Phosphagenics
Limited ("Phosphagenics"), the Australian Stock Exchange (ASX : POH) and the
London Stock Exchange's Alternative Investment Market (AIM : PSG) listed
pharmaceutical and nutraceutical company, and Nestlé Nutrition, a unit of
Nestlé S.A. the world's biggest food and beverage company, today announce that
they have entered into a research agreement to develop Phosphagenics' Phospha E
® for use in Nestlé Nutrition's products. Products containing this superior
form of vitamin E have the potential to play a role in the prevention and
treatment of metabolic syndrome.
Under the terms of the agreement, Nestlé Nutrition will contribute some of the
funding towards a full dose-response preclinical study of Phospha E®, before
full scale evaluation of the product in humans. Phospha E® has been shown in
animal trials to lower blood cholesterol and triglyceride levels and to prevent
or reduce arterial plaque formation, as well as inhibiting the main
inflammatory pathways involved in metabolic syndrome.
In return, Nestlé Nutrition has obtained an option to license Phospha E® for
its use in nutritional products that target the prevention and treatment of
metabolic syndrome. Upon completion of the preclinical trials, Nestlé Nutrition
may exercise its option, upon payment of an option fee. The agreement requires
that Nestlé Nutrition launch a product within 12 months of regulatory approval
of the product and claims, and that Phosphagenics will be responsible for the
manufacture of and sale to Nestle Nutrition of Phospha E®.
Harry Rosen, Managing Director of Phosphagenics, said "Phosphagenics is
delighted to have signed this agreement with Nestlé Nutrition, which builds on
our collaborative work so far. As one of the world's largest nutrition
companies, Nestlé Nutrition is the ideal partner to exploit the potential of
Phospha E® in nutritional products".
END
About metabolic syndrome
Metabolic syndrome is a multifactorial risk factor for cardiovascular disease
and diabetes. The root causes of metabolic syndrome are overweight/obesity,
physical inactivity, and genetic factors. It is estimated that about 27% of
adults in the US have metabolic syndrome and that one in three overweight or
obese people in the US have this condition. The condition is being diagnosed
with increasing frequency.
About Phosphagenics
Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for dietary supplements, functional foods and personal care
products. It is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). Further information regarding Phosphagenics can be
found at www.phosphagenics.com.
About Nestlé Nutrition
Nestlé Nutrition is an autonomous business operation within the Nestlé group
that manages and develops the group's core nutrition business. Through
science-based nutrition products and services, Nestlé Nutrition will help
enhance the quality of people's lives by supporting health and providing care
for specific consumer groups with special nutrition needs at every stage of
life. Its product portfolio - covering infant nutrition, healthcare nutrition,
and performance nutrition - includes such trusted and well-recognised brands
as: NAN, LACTOGEN, NESLAC, NUTREN, PEPTAMEN and POWERBAR.
For further information please contact:
Australia:
Phosphagenics Limited : Harry Rosen, Managing Director
Telephone: +61 3 9605 5900
UK:
Northbank Communications: Rowan Minnion
Telephone: +44 7886 8150
r.minnion@northbankcommunications.com
END

That's what I've got!! metabolic syndrome-where can I buy some??? lol